Compare AIV & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | WVE |
|---|---|---|
| Founded | 1975 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1994 | 2015 |
| Metric | AIV | WVE |
|---|---|---|
| Price | $5.74 | $16.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $10.00 | ★ $25.93 |
| AVG Volume (30 Days) | 1.6M | ★ 12.6M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | ★ 49.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $210,889,000.00 | $109,230,000.00 |
| Revenue This Year | $6.96 | N/A |
| Revenue Next Year | N/A | $31.09 |
| P/E Ratio | $3.64 | ★ N/A |
| Revenue Growth | 39.67 | ★ 103.75 |
| 52 Week Low | $5.24 | $5.28 |
| 52 Week High | $9.29 | $21.73 |
| Indicator | AIV | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 68.44 |
| Support Level | $5.58 | $6.93 |
| Resistance Level | $5.62 | $21.73 |
| Average True Range (ATR) | 0.07 | 1.40 |
| MACD | 0.04 | 1.38 |
| Stochastic Oscillator | 89.47 | 66.75 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.